Wellington Management Group LLP Acquires 1,608,522 Shares of Savara Inc (NASDAQ:SVRA)

Wellington Management Group LLP increased its holdings in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 22.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,624,012 shares of the company's stock after purchasing an additional 1,608,522 shares during the quarter. Wellington Management Group LLP owned 5.03% of Savara worth $36,566,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Choreo LLC bought a new position in shares of Savara during the 2nd quarter worth approximately $59,000. DRW Securities LLC acquired a new stake in Savara during the 2nd quarter valued at $62,000. Principal Financial Group Inc. lifted its holdings in shares of Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock worth $72,000 after buying an additional 6,973 shares in the last quarter. Profund Advisors LLC acquired a new stake in shares of Savara during the second quarter worth $105,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company's stock worth $109,000 after buying an additional 18,534 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Insider Activity at Savara

In other news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on SVRA. HC Wainwright dropped their price target on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. JMP Securities reiterated a "market outperform" rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Finally, Evercore ISI reiterated an "in-line" rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $10.17.

Savara Stock Down 4.5 %

Shares of NASDAQ:SVRA traded down $0.15 during trading on Friday, reaching $3.20. 2,742,841 shares of the stock were exchanged, compared to its average volume of 1,266,135. The stock has a fifty day moving average of $3.53 and a two-hundred day moving average of $4.02. Savara Inc has a 1-year low of $2.82 and a 1-year high of $5.70. The firm has a market cap of $549.18 million, a price-to-earnings ratio of -7.74 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11). Research analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.